Clinical trial
A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma
NCT00265135 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma
- Lead sponsor
- Centocor, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 31, 2003
- Completion date
- February 28, 2006
- Enrollment
- 68 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.